title: Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
abstract: The Intergroupe Francophone du Myélome (IFM) initiated 2 trials in 1999 to study patients with high-risk (beta2-microglobulin level greater than 3 mg/L and chromosome 13 deletion at diagnosis) de novo multiple myeloma. In both protocols, the induction regimen consisted of vincristine, doxorubicin, and dexamethasone (VAD) followed by first autologous stem cell transplantation (ASCT) prepared by melphalan 200 mg/m(2). Patients with an HLA-identical sibling donor were subsequently treated with dose-reduced allogeneic stem cell transplantation (IFM99-03 trial), and patients without an HLA-identical sibling donor were randomly assigned to undergo second ASCT prepared by melphalan 220 mg/m(2) and 160 mg dexamethasone with or without anti-IL-6 monoclonal antibody (IFM99-04 protocol). Two hundred eighty-four patients-65 in the IFM99-03 trial and 219 in the IFM99-04 trial-were prospectively treated and received at least one course of VAD. On an intent-to-treat basis, overall survival (OS) and event-free survival (EFS) did not differ significantly in the studies (medians 35 and 25 months in the IFM99-03 trial vs 41 and 30 months in the IFM99-04 trial, respectively). With a median follow-up time of 24 months, the EFS of the 166 patients randomly assigned in the tandem ASCT protocol was similar to the EFS of the 46 patients who underwent the entire IFM99-03 program (median, 35 vs 31.7 months), with a trend for a better OS in patients treated with tandem ASCT (median, 47.2 vs 35 months; P = .07). In patients with high-risk de novo MM, the combination of ASCT followed by dose-reduced allogeneic transplantation was not superior to tandem dose-intensified, melphalan-based ASCT.
authors.affiliation: Hematology Department, University Hospital Hôtel-Dieu, Place Ricordeau, 44093 Nantes cedex 01, France.
authors.forename: Frederic
authors.initials: F
authors.lastname: Garban
authors.forename: Michel
authors.initials: M
authors.lastname: Attal
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Cyrille
authors.initials: C
authors.lastname: Hulin
authors.forename: Jean H
authors.initials: JH
authors.lastname: Bourhis
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Yakoub-Agha
authors.forename: Thierry
authors.initials: T
authors.lastname: Lamy
authors.forename: Gerald
authors.initials: G
authors.lastname: Marit
authors.forename: Frederic
authors.initials: F
authors.lastname: Maloisel
authors.forename: Christian
authors.initials: C
authors.lastname: Berthou
authors.forename: Mamoun
authors.initials: M
authors.lastname: Dib
authors.forename: Denis
authors.initials: D
authors.lastname: Caillot
authors.forename: Bernard
authors.initials: B
authors.lastname: Deprijck
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ketterer
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Sotto
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology; D006680:HLA Antigens; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D011446:Prospective Studies; D035781:Siblings; D015996:Survival Rate; D014019:Tissue Donors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens